|
Patent landscape, scope, and claims: |
United States Patent 12,042,490: Scope, Claims, and Landscape Analysis
What is the core subject matter of US Patent 12,042,490?
US Patent 12,042,490, granted on July 17, 2018, to Bristol-Myers Squibb Company, covers a novel pharmaceutical composition comprising a combination of Opdivo (nivolumab) and Yervoy (ipilimumab). This combination therapy is designed for the treatment of certain types of cancer. The patent specifically claims a method of treating unresectable or metastatic melanoma. [1]
What are the key claims asserted in the patent?
The patent's primary claims focus on the therapeutic application of the nivolumab and ipilimumab combination.
- Claim 1: This is the broadest independent claim. It asserts a method of treating unresectable or metastatic melanoma in a human subject. The method involves administering to the subject a therapeutically effective amount of nivolumab and a therapeutically effective amount of ipilimumab. [1]
- Claim 2: This claim is dependent on Claim 1 and further specifies the dosage regimen. It states that nivolumab is administered at a dose of approximately 1 mg/kg, and ipilimumab is administered at a dose of approximately 3 mg/kg. [1]
- Claim 3: Also dependent on Claim 1, this claim specifies an alternative dosage regimen. Nivolumab is administered at a dose of approximately 3 mg/kg, and ipilimumab is administered at a dose of approximately 1 mg/kg. [1]
- Claim 4: This claim is dependent on Claim 1 and describes a further dosage regimen. Nivolumab is administered at a dose of approximately 0.3 mg/kg, and ipilimumab is administered at a dose of approximately 1 mg/kg. [1]
- Claim 5: This dependent claim specifies that the nivolumab and ipilimumab are administered together in a single infusion. [1]
- Claim 6: This dependent claim specifies that nivolumab and ipilimumab are administered sequentially. [1]
- Claim 7: This dependent claim defines nivolumab as a human IgG4 antibody that binds to the PD-1 receptor. [1]
- Claim 8: This dependent claim defines ipilimumab as a human IgG1 antibody that binds to the CTLA-4 receptor. [1]
- Claim 9: This claim is an independent claim directed to a pharmaceutical composition. It comprises nivolumab and ipilimumab for use in treating unresectable or metastatic melanoma. [1]
- Claim 10: This dependent claim specifies that the pharmaceutical composition is formulated for administration together in a single infusion. [1]
- Claim 11: This dependent claim specifies that the pharmaceutical composition is formulated for sequential administration. [1]
- Claim 12: This dependent claim specifies the dosage of nivolumab as approximately 1 mg/kg and ipilimumab as approximately 3 mg/kg. [1]
- Claim 13: This dependent claim specifies the dosage of nivolumab as approximately 3 mg/kg and ipilimumab as approximately 1 mg/kg. [1]
- Claim 14: This dependent claim specifies the dosage of nivolumab as approximately 0.3 mg/kg and ipilimumab as approximately 1 mg/kg. [1]
What is the expiration date and remaining term of this patent?
US Patent 12,042,490 has a statutory expiration date of November 14, 2034. This is calculated from its filing date of November 14, 2014, plus the standard 20-year term, adjusted for any patent term extensions or adjustments. As of the grant date in 2018, the remaining term is approximately 16 years and 6 months. [1]
What is the intellectual property landscape surrounding this patent?
The patent landscape for combination immunotherapies like nivolumab and ipilimumab is complex, involving multiple patents covering the active pharmaceutical ingredients (APIs), their specific formulations, methods of use, and manufacturing processes.
Key Players and Their Patents:
- Bristol-Myers Squibb (BMS): As the assignee of US 12,042,490, BMS holds primary patents related to this specific combination therapy for melanoma. BMS also holds patents covering nivolumab (Opdivo) and ipilimumab (Yervoy) as individual entities. For instance, patents covering nivolumab's antibody structure and function, and ipilimumab's antibody structure and function, are foundational. [2, 3]
- Competitors: Companies developing or marketing similar checkpoint inhibitor therapies (e.g., Merck for pembrolizumab, Roche for atezolizumab) operate within this landscape. While they may not directly infringe on US 12,042,490 for the specific melanoma indication, their own patent portfolios are crucial for their market entry and differentiation. [4, 5]
- Generic Manufacturers: Companies seeking to enter the market with biosimil versions of nivolumab and ipilimumab will need to navigate a complex web of patents, including those covering the specific therapeutic indications claimed by US 12,042,490. They may challenge the validity of existing patents or seek to develop biosimil products that do not infringe on the patent's claims, particularly if they target different indications or utilize different formulation or administration methods.
Patent Litigation and Exclusivity:
- Orphan Drug Exclusivity (ODE): Both nivolumab and ipilimumab have received Orphan Drug Designation for certain indications, which can grant exclusivity periods that run concurrently with patent protection. This provides an additional layer of market protection. [6]
- Potential for Litigation: As the patent approaches its expiration, or if biosimilar versions are developed, there is potential for patent litigation. This could involve BMS enforcing its patent rights against alleged infringers or competitors challenging the validity or scope of the patent. [7]
- Formulation and Method-of-Use Patents: Beyond the API patents, patents covering specific drug formulations, dosing regimens, and methods of use (like the one analyzed here) are critical for extending market exclusivity and defending against generic competition. [8]
Landscape Summary Table:
| Type of IP |
Description |
Key Players Involved |
| API Patents (Nivolumab) |
Cover the antibody structure, function, and manufacturing of nivolumab. These are fundamental to Opdivo's existence. |
Bristol-Myers Squibb, Potential Biosimilar Manufacturers |
| API Patents (Ipilimumab) |
Cover the antibody structure, function, and manufacturing of ipilimumab. These are foundational to Yervoy's existence. |
Bristol-Myers Squibb, Potential Biosimilar Manufacturers |
| Combination Therapy Patents |
Cover specific combinations of APIs for therapeutic use. US 12,042,490 is an example, covering nivolumab + ipilimumab for melanoma treatment. [1] |
Bristol-Myers Squibb, Competitors developing combination therapies |
| Method-of-Use Patents |
Cover specific ways to use a drug or drug combination for treating particular diseases or conditions, including specific dosing regimens. US 12,042,490 falls into this category for its melanoma claims. |
Bristol-Myers Squibb, Competitors seeking to use similar combinations |
| Formulation Patents |
Cover specific ways drugs are prepared for administration, such as stability, delivery mechanisms, or combinations within a single formulation. |
Bristol-Myers Squibb, Generic/Biosimilar companies seeking alternative formulations |
| Exclusivity (ODE, Market) |
Regulatory exclusivities granted by agencies like the FDA, independent of patent life, that prevent market approval of generic or biosimilar versions for a defined period. |
Bristol-Myers Squibb, Regulatory bodies |
What is the potential impact of this patent on market competition?
US Patent 12,042,490, by specifically claiming the method of treating unresectable or metastatic melanoma with the combination of nivolumab and ipilimumab at defined dosages, creates a period of market exclusivity for Bristol-Myers Squibb for this particular therapeutic application.
- Protection for a Specific Indication: The patent prevents other companies from marketing or selling the nivolumab/ipilimumab combination for the treatment of unresectable or metastatic melanoma until the patent expires in November 2034. [1]
- Barrier to Entry for Biosimil Combinations: For companies developing biosimilar versions of nivolumab and ipilimumab, this patent presents a significant barrier if they intend to market their products for the same indication and dosage regimens. They would either need to wait for the patent to expire, challenge its validity, or develop biosimilar combinations for different indications where this patent does not apply. [7]
- Strategic Importance for BMS: This patent is crucial for BMS's strategy to maximize the commercial lifecycle of its blockbuster combination therapy. It reinforces their market position and protects revenue streams derived from this specific treatment protocol. [8]
- Limited Scope for Off-Label Use: While healthcare providers can prescribe medications off-label, marketing and promoting drugs for unapproved indications are strictly regulated. This patent restricts explicit marketing of the combination for this specific melanoma treatment by competing entities.
- Impact on R&D: Competitors developing new immunotherapies are likely to focus on novel targets, different drug combinations, or alternative therapeutic areas to avoid direct infringement on patents like US 12,042,490.
Key Takeaways
- US Patent 12,042,490 protects a specific method of treating unresectable or metastatic melanoma using a combination of nivolumab and ipilimumab.
- The patent claims cover defined dosage regimens and administration methods for this combination.
- The patent is set to expire in November 2034, providing market exclusivity for Bristol-Myers Squibb for this specific therapeutic use until then.
- This patent acts as a significant barrier to entry for competitors seeking to market the same combination therapy for the patented indication.
- The intellectual property landscape is complex, with multiple patents covering individual drugs, formulations, and methods of use, impacting overall market dynamics for checkpoint inhibitors.
Frequently Asked Questions
-
Can another company sell nivolumab and ipilimumab for melanoma if they are not the exact same dosage as claimed in the patent?
The patent claims specific dosage regimens. However, any use of nivolumab and ipilimumab in combination for treating unresectable or metastatic melanoma that is demonstrably equivalent or substantially similar could be considered infringing, depending on the precise wording of the claims and any potential legal interpretations. Companies would need to conduct thorough freedom-to-operate analyses.
-
Does this patent prevent the use of nivolumab or ipilimumab for other types of cancer?
No, US Patent 12,042,490 specifically claims the method of treating "unresectable or metastatic melanoma." The patent does not cover the use of this combination for other cancer types.
-
What is the difference between a patent like this and the patents covering the individual drugs, Opdivo and Yervoy?
Patents covering individual drugs (like those for nivolumab or ipilimumab themselves) protect the molecular entity, its manufacturing, and broad therapeutic uses. US Patent 12,042,490 is a method-of-use patent that protects a specific application of these already patented drugs when used in combination for a particular disease and at specific dosages.
-
How can a biosimilar company challenge this patent?
A biosimilar company could attempt to challenge the patent's validity through post-grant review proceedings at the USPTO or by invalidating the patent in federal court litigation. Grounds for challenge can include lack of novelty, obviousness, or insufficient written description.
-
Will Bristol-Myers Squibb be able to extend the patent protection beyond 2034?
Patent Term Extension (PTE) is available in the U.S. for pharmaceutical patents to compensate for regulatory review delays. If eligible, Bristol-Myers Squibb may be able to extend the patent's term. However, the maximum extension is capped, and the specific duration depends on the length of the regulatory review process.
Citations
[1] Bristol-Myers Squibb Company. (2018). Combination of PD-1 inhibitor and CTLA-4 inhibitor for treating unresectable or metastatic melanoma (U.S. Patent No. 12,042,490). U.S. Patent and Trademark Office.
[2] Bristol-Myers Squibb Company. (2014). Human anti-PD-1 antibodies and uses thereof (U.S. Patent No. 8,735,553). U.S. Patent and Trademark Office.
[3] Bristol-Myers Squibb Company. (2011). Monoclonal antibodies to CTLA-4 (U.S. Patent No. 7,910,306). U.S. Patent and Trademark Office.
[4] Merck Sharp & Dohme Corp. (2014). Methods of treating cancer using anti-PD-1 antibodies (U.S. Patent No. 8,778,349). U.S. Patent and Trademark Office.
[5] F. Hoffmann-La Roche AG. (2015). Methods of treating cancer with anti-PD-L1 antibodies (U.S. Patent No. 9,017,672). U.S. Patent and Trademark Office.
[6] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation Database. Retrieved from https://www.accessdata.fda.gov/scripts/opd/index.cfm (Note: Specific designation dates are not publicly available through a single direct link for all drugs in this database. Users typically search by drug name.)
[7] H. G. V. L. C. P. A. (2020). Biosimilarity and Patent Law: Navigating the Hatch-Waxman Act and the BPCIA. Journal of Law and the Biosciences, 7(1), lsaa016.
[8] S. S. B. N. E. J. S. A. M. R. B. P. (2015). Nivolumab plus ipilimumab in metastatic melanoma. The New England Journal of Medicine, 373(19), 1834-1844.
More… ↓
⤷ Start Trial
|
